GSK plc & Merck & Co.
8 shared events · Importance 3 · Last updated Aug 13, 2026
Live sentiment trends, interaction importance charts, and action volume tracking available on the
Ergen Dashboard
Regulatory
GSK plc: GSK plc is among the pharmaceutical companies that agreed to lower drug prices for United States — Medicaid and cash payers as part of the deals with the Donald Trump administration.
Merck & Co.: Merck & Co. struck a deal to cut prices, committing to sell its diabetes drugs Januvia, Janumet, and Janumet XR at 70% off list prices directly to US consumers and pledging $70 billion in US R&D and manufacturing investments.
Dec 19, 2025 · 7 articles
Domestic
GSK plc: Another vaccine manufacturer, it also criticized the order and faces potential business implications if separate vaccines are developed.
Merck & Co.: Manufacturer of the MMR vaccine, stated no scientific benefit to splitting it. Faces potential regulatory and market pressure if separate vaccines are developed, but currently no immediate financial impact.
Aug 10, 2026 · 235 articles
Regulatory
GSK plc: GSK plc benefits from the expanded label of the VENTANA MMR RxDx Panel as it identifies patients eligible for its Dostarlimab therapy, potentially increasing the drug's market reach.
Merck & Co.: Merck & Co. benefits from the expanded label of the VENTANA MMR RxDx Panel as it identifies patients eligible for its Pembrolizumab therapy, potentially increasing the drug's market reach.
Jun 11, 2026 · 6 articles
Tech
GSK plc: GSK plc>>>'s drug Avodart is mentioned in a comparison study where GLP-1s were associated with lower rates of prostate cancer diagnoses.
Merck & Co.: Merck & Co.>>>'s immunotherapy Keytruda is mentioned as potentially faring better when patients are also taking GLP-1 drugs, suggesting a possible interaction with the immune system.
Jun 02, 2026 · 45 articles
Domestic
GSK plc: GSK plc, a hepatitis B vaccine maker, defended its products as safe, and its shares finished 0.3% lower.
Merck & Co.: Merck & Co., a hepatitis B vaccine maker, expressed deep concern over the ACIP's vote, and its shares closed down 1.2% on Friday.
Dec 05, 2025 · 7 articles
Business
GSK plc: GSK plc's acquisition of Nuvalent Inc. is another example of big pharma M&A that supports biotech valuations.
Merck & Co.: Merck's Lipfendra, the first FDA-approved PCSK9 pill, competes with Scribe's STX-1150. Scribe's epigenetic approach may differentiate it.
Jul 06, 2026 · 25 articles
Business
GSK plc: GSK plc has adopted a more aggressive M&A approach following recent CEO transitions, contributing to the overall increase in dealmaking.
May 01, 2026 · 6 articles
ERGEN INTELLIGENCE
Explore this relationship live
Track how GSK plc and Merck & Co. interact across events, view sentiment trends, and discover connected entities.
Open Dashboard